Monteverde & Associates launches shareholder investigation into Neuphoria Therapeutics, raising potential legal exposure for the NASDAQ‑listed biotech
Executive summary: Monteverde & Associates PC announced an investigation of Neuphoria Therapeutics (NASDAQ: NEUP) for potential securities law violations. The probe adds Neuphoria to a series of similar alerts from the same firm, indicating heightened legal risk that could trigger a class‑action suit and affect the company's share price and financing ability.
Who is involved: Monteverde & Associates PC (lead attorney Juan Monteverde), Neuphoria Therapeutics Inc., its shareholders, and potentially the SEC.
Likely next: If the investigation uncovers actionable claims, the firm may seek lead plaintiff status and file a class‑action complaint, with a lead‑plaintiff deadline likely in early August 2026.
On July 24, 2026, the M&A Class Action Firm disclosed that it is investigating Neuphoria Therapeutics Inc. (NASDAQ: NEUP) for possible securities law violations, following its pattern of filing alerts for other publicly traded companies. The firm notes it has recovered millions for shareholders and is ranked among the top 50 class‑action practices. While no specific allegations are detailed, the announcement signals heightened scrutiny that could lead to a class‑action lawsuit if sufficient investor losses are identified.
Timeline
- — $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Neuphoria Therapeutics, Inc. (NASDAQ: NEUP) (PR Newswire)
- — $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Safety Insurance Group Inc. (NASDAQ: SAFT) (PR Newswire)
- — $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Northrim Bancorp, Inc. (NASDAQ: NRIM) (PR Newswire)
Analysis — what this means
Likely next events
- Lead plaintiff deadline for a potential class action likely early August 2026.
- Monteverde & Associates may file a securities fraud complaint by mid‑August 2026 if sufficient shareholder losses are documented.
Sectors affected
- Biotechnology
- Pharmaceuticals
- NASDAQ‑listed NEUP
Regulatory implications
- Possible SEC investigation under Section 10(b) of the Securities Exchange Act if misstatements are found.
Historical parallels
- Monteverde & Associates investigated Northrim Bancorp (NASDAQ: NRIM) on July 23, 2026.
- The same firm announced an investigation of Safety Insurance Group (NASDAQ: SAFT) on July 24, 2026.
Key entities
Sources
- $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Neuphoria Therapeutics, Inc. (NASDAQ: NEUP) — PR Newswire
- $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Safety Insurance Group Inc. (NASDAQ: SAFT) — PR Newswire
- $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Northrim Bancorp, Inc. (NASDAQ: NRIM) — PR Newswire
Related cases
- Regeneron investors urged to join class‑action lawsuit over alleged securities fraud during 2025‑26 stock period
- Ademi LLP’s probe into the $1.14 per share GoPro buyout raises shareholder concerns over possible undervaluation in a $285 million transaction
- Robbins Geller alerts HIMS investors of Nov 2 deadline to lead class action over alleged securities fraud
- Levi & Korsinsky launches fiduciary‑duty probe into Arlo Technologies officers and directors
- SEC‑style investigation launched into EyePoint Inc. over alleged securities law violations, prompting investor outreach to KTMC Law Firm
- Pomerantz LLP is investigating potential claims on behalf of Metropolitan Bank Holding Corp. shareholders, signaling possible litigation risk for the bank